Stock Track | Moderna Soars 5.06% Intraday as FDA Reverses Course on Flu Vaccine Review

Stock Track

Feb 20

Moderna, Inc.'s stock soared 5.06% during intraday trading on Thursday, following a significant positive development regarding its regulatory pipeline.

The surge comes after the U.S. Food and Drug Administration reversed its previous decision and agreed to review an amended application for Moderna's mRNA-1010 seasonal influenza vaccine. This follows a "refusal-to-file" letter issued by the agency just last week, which had initially rejected the submission and raised concerns among investors.

Analysts have responded positively to the swift regulatory U-turn. William Blair raised its probability of regulatory success for the flu vaccine to 55% from a previous estimate of 10%. The development improves the prospects for Moderna's vaccine candidate, which is seeking approval for adults aged 50 and older, potentially making it available for the 2026-2027 flu season.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1167324353"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1167324353\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1167324353?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-20 02:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167324353","market":"us","top_or_hot":-1,"title":"Stock Track | Moderna Soars 5.06% Intraday as FDA Reverses Course on Flu Vaccine Review","media":"Stock Track","content":"<p>Moderna, Inc.'s stock soared 5.06% during intraday trading on Thursday, following a significant positive development regarding its regulatory pipeline.</p><p>The surge comes after the U.S. Food and Drug Administration reversed its previous decision and agreed to review an amended application for Moderna's mRNA-1010 seasonal influenza vaccine. This follows a \"refusal-to-file\" letter issued by the agency just last week, which had initially rejected the submission and raised concerns among investors.</p><p>Analysts have responded positively to the swift regulatory U-turn. William Blair raised its probability of regulatory success for the flu vaccine to 55% from a previous estimate of 10%. The development improves the prospects for Moderna's vaccine candidate, which is seeking approval for adults aged 50 and older, potentially making it available for the 2026-2027 flu season.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Moderna Soars 5.06% Intraday as FDA Reverses Course on Flu Vaccine Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Moderna Soars 5.06% Intraday as FDA Reverses Course on Flu Vaccine Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-20 02:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna, Inc.'s stock soared 5.06% during intraday trading on Thursday, following a significant positive development regarding its regulatory pipeline.</p><p>The surge comes after the U.S. Food and Drug Administration reversed its previous decision and agreed to review an amended application for Moderna's mRNA-1010 seasonal influenza vaccine. This follows a \"refusal-to-file\" letter issued by the agency just last week, which had initially rejected the submission and raised concerns among investors.</p><p>Analysts have responded positively to the swift regulatory U-turn. William Blair raised its probability of regulatory success for the flu vaccine to 55% from a previous estimate of 10%. The development improves the prospects for Moderna's vaccine candidate, which is seeking approval for adults aged 50 and older, potentially making it available for the 2026-2027 flu season.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1167324353","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167324353","pubTimestamp":1771527542,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Moderna, Inc.'s stock soared 5.06% during intraday trading on Thursday, following a significant positive development regarding its regulatory pipeline.The surge comes after the U.S. Food and Drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"个股追踪|Moderna盘中大涨5.06%FDA逆转流感疫苗审查","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"Moderna, Inc.'s stock soared 5.06% during intraday trading on Thursday, following a significant positive development regarding its regulatory pipeline.The surge comes after the U.S. Food and Drug Administration reversed its previous decision and agreed to review an amended application for Moderna's mRNA-1010 seasonal influenza vaccine. This follows a \"refusal-to-file\" letter issued by the agency just last week, which had initially rejected the submission and raised concerns among investors.Analysts have responded positively to the swift regulatory U-turn. William Blair raised its probability of regulatory success for the flu vaccine to 55% from a previous estimate of 10%. The development improves the prospects for Moderna's vaccine candidate, which is seeking approval for adults aged 50 and older, potentially making it available for the 2026-2027 flu season.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}